CAR-T webinar | Pharmetheus

Webinar overview

Chimeric Antigen Receptor (CAR)-T cell therapies have transformed the treatment of hematological malignancies. However, developing these "living drugs" presents a unique challenge. Unlike small molecules or conventional biologics, CAR-T cells actively proliferate inside the patient. This means standard dose-optimization strategies, where a higher dose typically leads to higher exposure, cannot be applied.

To successfully develop current and future cell therapies, the industry must apply tailored quantitative tools. Importantly, commonly used empirical models are not designed to predict how these therapies will behave prospectively under conditions that differ from those used for model building. Instead, frameworks that consider the biological drivers of cellular expansion are needed to support extrapolations and simulations of unobserved scenarios.

Dr. Anna Mc Laughlin will explore how to apply Model-Informed Drug Development (MIDD) to cell therapy in oncology.

Webinar overview

Key topics covered

Presenters & Hosts

Target audience

Webinar details

Sign up to secure your spot